## NATIONAL INSTITUTE FOR HEALTH AND CARE **EXCELLENCE**

## **HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

## **Equality impact assessment – Scoping**

## STA Fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.	
1.	Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
No potential equality issues were raised.	
2.	What is the preliminary view as to what extent these potential equality issues need addressing by the committee?
Not applicable.	
3.	Has any change to the draft scope been agreed to highlight potential equality issues?
Not applicable.	
4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
Not applicable.	

Technology appraisals: Scoping

Equality impact assessment for the proposed single technology appraisal of fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer

1 of 2

Issue date: January 2017

Approved by Associate Director (name): ......Janet Robertson......

**Date:** 15 March 2017

Issue date: January 2017 2 of 2